H Umesha Shetty1, Sami S Zoghbi2, Jeih-San Liow2, Masanori Ichise2, Jinsoo Hong2, John L Musachio2, Christer Halldin3, Jurgen Seidel4, Robert B Innis2, Victor W Pike2. 1. PET Radiopharmaceutical Sciences, Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Building 10, Room B3 C351, MSC 1003, 10 Center Drive, Bethesda, MD, 20892-1003, USA. shettyu@mail.nih.gov. 2. PET Radiopharmaceutical Sciences, Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Building 10, Room B3 C351, MSC 1003, 10 Center Drive, Bethesda, MD, 20892-1003, USA. 3. Department of Clinical Neuroscience, Psychiatry Section, Karolinska Hospital, Stockholm, Sweden. 4. Department of Nuclear Medicine, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Abstract
PURPOSE: We aimed to determine the composition of radioactivity in rat brain after intravenous administration of the dopamine transporter radioligand, [(11)C]PE2I. METHODS: PET time-activity curves (TACs) and regional brain distribution ex vivo were measured using no-carrier-added [(11)C]PE2I. Carrier-added [(11)C]PE2I was administered to identify metabolites with high-performance liquid radiochromatography (RC) or RC with mass spectrometry (LC-MS and MS-MS). The stability of [(11)C]PE2I was assessed in rat brain homogenates. RESULTS: After peak brain uptake of no-carrier-added [(11)C]PE2I, there was differential washout rate from striata and cerebellum. Thirty minutes after injection, [(11)C]PE2I represented 10.9 +/- 2.9% of the radioactivity in plasma, 67.1 +/- 11.0% in cerebellum, and 92.5 +/- 3.2% in striata, and was accompanied by two less lipophilic radiometabolites. [(11)C]PE2I was stable in rat brain homogenate for at least 1 h at 37 degrees C. LC-MS identified hydroxylated PE2I (1) (m/z 442) and carboxyl-desmethyl-PE2I (2) (m/z 456) in brain. MS-MS of 1 gave an m/z 442-->424 transition due to H(2)O elimination, so verifying the presence of a benzyl alcohol group. Metabolite 2 was the benzoic acid derivative. Ratios of ex vivo measurements of [(11)C]PE2I, [(11)C]1, and [(11)C]2 in striata to their cognates in cerebellum were 6.1 +/- 3.4, 3.7 +/- 2.2 and 1.33 +/- 0.38, respectively, showing binding selectivity of metabolite [(11)C]1 to striata. CONCLUSION: Radiometabolites [(11)C]1 and [(11)C]2 were characterized as the 4-hydroxymethyl and 4-carboxyl analogs of [(11)C]PE2I, respectively. The presence of the pharmacologically active [(11)C]1 and the inactive [(11)C]2 is a serious impediment to successful biomathematical analysis.
PURPOSE: We aimed to determine the composition of radioactivity in rat brain after intravenous administration of the dopamine transporter radioligand, [(11)C]PE2I. METHODS: PET time-activity curves (TACs) and regional brain distribution ex vivo were measured using no-carrier-added [(11)C]PE2I. Carrier-added [(11)C]PE2I was administered to identify metabolites with high-performance liquid radiochromatography (RC) or RC with mass spectrometry (LC-MS and MS-MS). The stability of [(11)C]PE2I was assessed in rat brain homogenates. RESULTS: After peak brain uptake of no-carrier-added [(11)C]PE2I, there was differential washout rate from striata and cerebellum. Thirty minutes after injection, [(11)C]PE2I represented 10.9 +/- 2.9% of the radioactivity in plasma, 67.1 +/- 11.0% in cerebellum, and 92.5 +/- 3.2% in striata, and was accompanied by two less lipophilic radiometabolites. [(11)C]PE2I was stable in rat brain homogenate for at least 1 h at 37 degrees C. LC-MS identified hydroxylated PE2I (1) (m/z 442) and carboxyl-desmethyl-PE2I (2) (m/z 456) in brain. MS-MS of 1 gave an m/z 442-->424 transition due to H(2)O elimination, so verifying the presence of a benzyl alcohol group. Metabolite 2 was the benzoic acid derivative. Ratios of ex vivo measurements of [(11)C]PE2I, [(11)C]1, and [(11)C]2 in striata to their cognates in cerebellum were 6.1 +/- 3.4, 3.7 +/- 2.2 and 1.33 +/- 0.38, respectively, showing binding selectivity of metabolite [(11)C]1 to striata. CONCLUSION: Radiometabolites [(11)C]1 and [(11)C]2 were characterized as the 4-hydroxymethyl and 4-carboxyl analogs of [(11)C]PE2I, respectively. The presence of the pharmacologically active [(11)C]1 and the inactive [(11)C]2 is a serious impediment to successful biomathematical analysis.
Authors: J T Kuikka; J L Baulieu; J Hiltunen; C Halldin; K A Bergström; L Farde; P Emond; S Chalon; M Yu; T Nikula; T Laitinen; J Karhu; E Tupala; T Hallikainen; V Kolehmainen; L Mauclaire; B Maziere; J Tiihonen; D Guilloteau Journal: Eur J Nucl Med Date: 1998-05
Authors: J H Meyer; S Krüger; A A Wilson; B K Christensen; V S Goulding; A Schaffer; C Minifie; S Houle; D Hussey; S H Kennedy Journal: Neuroreport Date: 2001-12-21 Impact factor: 1.837
Authors: D Xing; P Chen; R Keil; C D Kilts; B Shi; V M Camp; G Malveaux; T Ely; M J Owens; J Votaw; M Davis; J M Hoffman; R A BaKay; T Subramanian; R L Watts; M M Goodman Journal: J Med Chem Date: 2000-02-24 Impact factor: 7.446
Authors: R B Innis; J P Seibyl; B E Scanley; M Laruelle; A Abi-Dargham; E Wallace; R M Baldwin; Y Zea-Ponce; S Zoghbi; S Wang Journal: Proc Natl Acad Sci U S A Date: 1993-12-15 Impact factor: 11.205
Authors: R T Malison; C J McDougle; C H van Dyck; L Scahill; R M Baldwin; J P Seibyl; L H Price; J F Leckman; R B Innis Journal: Am J Psychiatry Date: 1995-09 Impact factor: 18.112
Authors: D Guilloteau; P Emond; J L Baulieu; L Garreau; Y Frangin; L Pourcelot; L Mauclaire; J C Besnard; S Chalon Journal: Nucl Med Biol Date: 1998-05 Impact factor: 2.408
Authors: Nicholas Seneca; Sami S Zoghbi; H Umesha Shetty; Edward Tuan; Pavitra Kannan; Andrew Taku; Robert B Innis; Victor W Pike Journal: Nucl Med Biol Date: 2010-04 Impact factor: 2.408
Authors: Anat Maoz; Martin J Hicks; Shankar Vallabhjosula; Michael Synan; Paresh J Kothari; Jonathan P Dyke; Douglas J Ballon; Stephen M Kaminsky; Bishnu P De; Jonathan B Rosenberg; Diana Martinez; George F Koob; Kim D Janda; Ronald G Crystal Journal: Neuropsychopharmacology Date: 2013-05-10 Impact factor: 7.853